Skip to main content

Table 1 Clinical data and demographics corresponding to urine samples from subjects with or without G2019S-LRRK2 mutations, with or without PD

From: Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers

 

LRRK2+/PD-

LRRK2+/PD+

LRRK2-/PD+

LRRK2-/PD-

p valuea

Gender M(F)

29(30)

8(18)

23(16)

2(6)

ns

Age

60 (52-66)

59 (53.75-70.25)

59 (53-63)

60.5 (56-75)

ns

Age at onset

NA

55 (47-60.25)

55 (50-60)

NA

ns

LEDD

NA

500 (400-650)

300 (0-600)

NA

ns

UPDRS_III

4 (0-6)

19.5 (15.75-22.25)

19 (16.5-24)

0 (0-0)

<0.0001

MoCA

26 (26-29)

26 (25-27)

28 (26-28)

27 (<26-30)

ns

H&Y

0 (0-0)

2 (2-2.5)

2 (2-2)

0 (0-0)

<0.0001

  1. LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (gender and MoCA), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)